Sanofi licenses novel monoclonal from Glenmark for up to $663 million
This article was originally published in Scrip
Executive Summary
In a significant move that may switch the image of India in biologics from a follower to a leader, Glenmark Pharmaceuticals has granted French drugs giant Sanofi a licence for the development and commercialisation of a novel monoclonal antibody for the treatment of Crohn's disease and other chronic autoimmune conditions. The deal involves a $50 million up front payment to Glenmark.